Cargando…
The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan
OBJECTIVES/HYPOTHESIS: Dupilumab, which blocks the shared receptor component for interleukin‐4 and interleukin‐13, reduced polyp size, sinus opacification, and symptom severity, and was well tolerated in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the SINUS‐52 study (NCT028984...
Autores principales: | Fujieda, Shigeharu, Matsune, Shoji, Takeno, Sachio, Asako, Mikiya, Takeuchi, Makiko, Fujita, Hiroyuki, Takahashi, Yoshinori, Amin, Nikhil, Deniz, Yamo, Rowe, Paul, Mannent, Leda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247406/ https://www.ncbi.nlm.nih.gov/pubmed/33226139 http://dx.doi.org/10.1002/lary.29230 |
Ejemplares similares
-
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
por: Fujieda, Shigeharu, et al.
Publicado: (2021) -
Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps
por: Bhattacharyya, Neil, et al.
Publicado: (2019) -
Development of Sinonasal Outcome Test (SNOT‐22) Domains in Chronic Rhinosinusitis With Nasal Polyps
por: Khan, Asif H., et al.
Publicado: (2021) -
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
por: Chuang, Chien‐Chia, et al.
Publicado: (2021) -
Fungal extracts detected in eosinophilic chronic rhinosinusitis induced cytokines from the nasal polyp cells
por: Hirotsu, Mikio, et al.
Publicado: (2014)